Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07511062
PHASE1
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Sponsor: Northside Hospital, Inc.
View on ClinicalTrials.gov
Summary
Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients
Official title: Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2026-08-01
Completion Date
2030-08-01
Last Updated
2026-04-06
Healthy Volunteers
No
Conditions
Interventions
DRUG
Decitabine
20mg/m2/d x5 days (induction \& consolidation)
DRUG
Venetoclax
400mg/d x14 days (induction); 400mg/d x7 days (consolidation)
DRUG
Axatilimab
Dose escalation, given on Days 1 and 15 of each cycle
Locations (1)
Northside Hospital, Inc.
Atlanta, Georgia, United States